Association between serum uric acid and prostate cancer mortality in androgen deprivation therapy: A population‐based cohort study

Yan Hiu Athena Lee,Jeffrey Shi Kai Chan,Chi Ho Leung,Jeremy Man Ho Hui,Edward Christopher Dee,Kenrick Ng,Kang Liu,Tong Liu,Gary Tse,Chi Fai Ng
DOI: https://doi.org/10.1002/cam4.6344
IF: 4.711
2023-07-18
Cancer Medicine
Abstract:Amongst patients with prostate cancer undergoing androgen deprivation therapy, a J‐shape relationship exists between baseline uric acid level and the risk of prostate cancer‐related mortality, with both high and low uric acid levels being associated with similarly elevated risks when compared against normal uric acid levels. Objective This population‐based study examined the association between baseline uric acid (UA) and prostate cancer (PCa)‐related mortality amongst PCa patients receiving androgen deprivation therapy (ADT). Methods Adults with PCa who received ADT in Hong Kong between December 1999 and March 2021 were identified. Patients with missing baseline UA were excluded. Patients were followed up until September 2021. The outcome was PCa‐related mortality. Results Altogether, 4126 patients (median follow‐up 3.1[interquartile range 1.4–6.0] years) were included. A J‐shaped association was observed between baseline UA level and PCa‐related mortality risk, with a direct association in those with mean(0.401 mmol/L) or above‐mean baseline UA levels (hazard ratio (HR) per standard deviation‐increase 1.35 [95% confidence interval 1.21,1.51], p
oncology
What problem does this paper attempt to address?